Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12173131 | 0.98 | NCF1 (0.43) | NCF1KDM4EPOLBRAB9AMEN1 | |
| SCHEMBL23634037 | 0.89 | KDM4E (0.46) | NCF1KDM4EPOLBRAB9AMEN1 | |
| SCHEMBL25696235 | 0.88 | KDM4E (0.41) | NCF1KDM4EPOLBRAB9AMEN1 | |
| SCHEMBL12173129 | 0.88 | KDM4E (0.41) | NCF1KDM4EPOLBRAB9AMEN1 | |
| SCHEMBL29837272 | 0.87 | KDM4E (0.50) | KDM4EPOLBRAB9AMEN1KMT2A | |
| SCHEMBL23634035 | 0.87 | KDM4E (0.50) | KDM4EPOLBRAB9AMEN1KMT2A | |
| SCHEMBL12173133 | 0.84 | PIK3CD (0.46) | KDM4EPOLBRAB9AMEN1KMT2A | |
| SCHEMBL20334306 | 0.84 | TSHR (0.44) | NCF1KDM4EPOLBRAB9AMEN1 | |
| SCHEMBL16322624 | 0.83 | KDM4E (0.50) | KDM4EPOLBRAB9AMEN1KMT2A | |
| SCHEMBL31237102 | 0.83 | KDM4E (0.50) | KDM4EPOLBRAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2008-02-07 | — | — | US | claimed |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2005-03-17 | — | — | US | claimed |
| EP-1326831-A1 | SUBSTITUTED FUSED PYRROLEIMINES AND PYRAZOLEIMINES | NEUROGEN CORPORATION (US) | 2003-07-16 | — | — | EP | claimed |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2002-09-12 | — | — | US | claimed |
| WO-2002020480-A1 | SUBSTITUTED FUSED PYRROLEIMINES AND PYRAZOLEIMINES | NEUROGEN CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2008-02-07 | — | — | US | disclosed |
| US-7282498-B2 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2005-03-17 | — | — | US | disclosed |
| US-6743817-B2 | AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR BRAIN RECEPTORS; ANXIOLYTICS, ANTIDEPRESSANTS, TREATING SLEEP AND PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NPSR1, GABRE, CHRNE | NCF1 3389/4885KDM4E 986/4885POLB 1781/4885 |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | HTR1A, GABRA1, GABRE | NCF1 2863/4885KDM4E 876/4885POLB 1532/4885 |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NPSR1, GABRE, CHRNE | NCF1 3389/4885KDM4E 986/4885POLB 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.